Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

December 18, 2025 by InsiderTrades.com

Key Points

CFO Terrance Coyne sold 69,582 shares on December 15 at an average price of $38.36 for about $2.67 million, leaving him with 43,510 shares — a 61.53% reduction in his ownership.
Royalty Pharma shares trade around $38.31 with a market cap of $22.11 billion and a P/E of 29.02; the company pays a $0.22 quarterly dividend (2.3% yield) and has a payout ratio of about 66.7%.
Analysts hold a consensus Moderate Buy rating with an average target of $45.60 and several recent buy ratings and targets in the mid-$40s.

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $38.32, for a total transaction of $766,400.00. Following the sale, the executive vice president directly owned 140,000 shares in the company, valued at $5,364,800. This trade represents a 12.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks

Marshall Urist also recently made the following trade(s):

On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total transaction of $913,526.10.
On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $714,174.30.
On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The stock was sold at an average price of $39.93, for a total value of $931,686.69.
On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total value of $727,855.80.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $38.52 on Thursday. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $22.23 billion, a PE ratio of 29.15, a price-to-earnings-growth ratio of 2.02 and a beta of 0.47. The firm's 50 day moving average price is $38.26 and its 200-day moving average price is $36.69. Royalty Pharma PLC has a twelve month low of $24.05 and a twelve month high of $41.24.

1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, beating analysts' consensus estimates of $1.11 by $0.06. The business had revenue of $609.29 million during the quarter, compared to analysts' expectations of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. Equities research analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th were paid a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.3%. The ex-dividend date was Friday, November 14th. Royalty Pharma's dividend payout ratio is presently 66.67%.

Institutional Investors Weigh In On Royalty Pharma

4 Healthcare Stocks With Massive Gains—and More to Come

Several hedge funds and other institutional investors have recently made changes to their positions in RPRX. CWM LLC grew its holdings in shares of Royalty Pharma by 1.5% during the third quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company's stock valued at $656,000 after buying an additional 281 shares during the last quarter. Augustine Asset Management Inc. lifted its position in Royalty Pharma by 4.4% during the 2nd quarter. Augustine Asset Management Inc. now owns 6,722 shares of the biopharmaceutical company's stock worth $242,000 after acquiring an additional 283 shares during the period. GAMMA Investing LLC grew its stake in Royalty Pharma by 9.6% during the 3rd quarter. GAMMA Investing LLC now owns 3,306 shares of the biopharmaceutical company's stock valued at $117,000 after purchasing an additional 289 shares during the last quarter. Hudson Bay Capital Management LP increased its holdings in shares of Royalty Pharma by 1.0% in the third quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company's stock valued at $1,037,000 after purchasing an additional 289 shares during the period. Finally, Merit Financial Group LLC raised its stake in shares of Royalty Pharma by 3.5% in the third quarter. Merit Financial Group LLC now owns 9,149 shares of the biopharmaceutical company's stock worth $323,000 after purchasing an additional 306 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on RPRX. The Goldman Sachs Group started coverage on shares of Royalty Pharma in a report on Tuesday, September 30th. They issued a "buy" rating and a $42.00 target price on the stock. Wall Street Zen lowered Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 28th. Leerink Partners set a $45.00 target price on Royalty Pharma in a research report on Thursday, December 11th. Cowen restated a "buy" rating on shares of Royalty Pharma in a report on Thursday, December 11th. Finally, TD Cowen raised their target price on shares of Royalty Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a report on Thursday, December 11th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $45.60.

Read Our Latest Stock Report on Royalty Pharma

About Royalty Pharma

(Get Free Report)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.